Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Unigene Stories

2012-12-12 08:27:50

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will...

2012-12-11 08:27:41

BOONTON, N.J., Dec. 11, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has retained Canaccord Genuity to assist the Company with its exploration and evaluation of a broad range of strategic options, including, but not limited to, the strategic partnering of its technology, the out-licensing of intellectual property and divestiture of certain assets, and the possible sale of the Company or one of its business units. There can be no assurance that any...

2012-11-27 08:28:40

BOONTON, N.J. and CAMBRIDGE, Mass., Nov. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announced that the companies have entered into a definitive licensing agreement to develop an oral formulation of TXA127, Tarix's lead peptide drug candidate. The oral formulation of TXA127 is being developed jointly by Unigene and Tarix under a previously agreed upon feasibility program whereby the companies leveraged Unigene's Peptelligence(TM)...

2012-11-20 08:27:43

BOONTON, N.J., Nov. 20, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a corporate review on key development programs and strategic initiatives, including the Company's ongoing progress following the debt financing and forbearance agreement with Victory Park Capital (VPC). Third Quarter Form 10-Q Filing The Company previously announced in a Current Report on Form 8-K filed with the SEC on November 9, 2012 that it would delay the filing of its Form 10-Q for the...

2012-11-16 12:25:55

BOONTON, N.J., Nov. 16, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that management will report third quarter 2012 financial results before market opens and host a conference call and live audio webcast on Tuesday, November 20, 2012 at 11 a.m., ET. Interested participants and investors may access the conference call at 11 a.m., ET by dialing 866-770-7129...

2012-10-16 07:28:04

BOONTON, N.J., Oct. 16, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its licensee, Tarsa Therapeutics, reported that a Phase 2 trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the...

2012-10-16 07:26:37

MINNEAPOLIS and PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced that a Phase II trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the lumbar spine. These data were presented at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting by Phase II investigator...

2012-10-15 07:29:07

BOONTON, N.J., Oct. 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women was the subject of an oral presentation given by Morten Karsdal, MSc, PhD, Chief Executive Officer of Nordic Bioscience, at the ASBMR...

2012-10-12 07:23:18

PHILADELPHIA, Oct.12, 2012 /PRNewswire/ -- Tarsa Therapeutics today announced an agreement in principle with Therapicon(®) Slr to provide consulting assistance to the Italian firm in its challenge to the recent recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to limit the use of calcitonin-containing medicines. Therapicon's request for a reexamination of the recommendation has been acknowledged by the CHMP, and a timetable for...

2012-09-26 02:26:24

BOONTON, N.J., Sept. 26, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the Company has entered into a Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement with affiliates of Victory Park Capital Advisors, LLC, dated September 21, 2012, whereby Victory Park Capital has loaned the Company $4 million and agreed to forbear from exercising certain rights due to designated events of default through September 21, 2013, subject to the...